Cytochrome P450 isoforms 1A1, 1B1 AND 2W1 as targets for therapeutic intervention in head and neck cancer

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Head and neck cancer (HNC) involves carcinogen exposure and drug-metabolizing enzymes (cytochrome P450s - CYPs) that detoxify or activate carcinogens.
• CYP enzymes play a role in HNC development and could be targets for therapy.
• Duocarmycin prodrugs require metabolic activation by specific enzymes.

Purpose of the Study:

• To investigate the expression of CYP1A1, CYP1B1, and CYP2W1 in head and neck cancer.
• To assess the potential of these CYPs as targets for activating duocarmycin prodrugs for selective HNC therapy.
• To evaluate the efficacy of duocarmycin prodrugs ICT2700 and ICT2706 in HNC models.

Main Methods:

• Gene expression analysis of CYP1A1, CYP1B1, and CYP2W1 in HNC cell lines, xenografts, and human samples.
• Measurement of CYP functional activity using P450-Glo™ assay in FaDu and Detroit-562 cells.
• Assessment of antiproliferative effects of duocarmycin prodrugs ICT2700 and ICT2706 on HNC cell lines.
• In vivo efficacy study of ICT2700 in mice bearing FaDu xenografts.

Main Results:

• CYP1A1 and CYP1B1 showed elevated gene expression in HNC cell lines, while CYP2W1 was minimally detected at the gene level but present in xenografts and human HNC samples.
• FaDu and Detroit-562 HNC cell lines were most sensitive to antiproliferative effects of ICT2700 and ICT2706.
• In vivo administration of ICT2700 demonstrated preferential inhibition of tumor growth in FaDu xenografts.

Conclusions:

• Intratumoral CYP expression can be exploited for metabolic activation of duocarmycin-based prodrugs.
• Duocarmycin prodrugs, such as ICT2700, show potential as a targeted therapeutic approach for head and neck cancer.
• This strategy offers a promising avenue for selective HNC therapy by leveraging specific enzyme activity within tumors.